Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) EBIT Margin (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBIT Margin for 2 consecutive years, with 51.12% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 17256.0% to 51.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 80.76%, a 8489.0% increase, with the full-year FY2025 number at 80.76%, up 8489.0% from a year prior.
  • EBIT Margin was 51.12% for Q4 2025 at Day One Biopharmaceuticals, up from 60.94% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 31.61% in Q3 2024 to a low of 1401.45% in Q2 2024.